FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer. PMID 40010771 · J Immunother Cancer · 2025-Feb-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, parallel-controlled, phase II clinical trial. PMID 40001034 · BMC Cancer · 2025-Feb-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip. PMID 40001000 · BMC Musculoskelet Disord · 2025-Feb-25 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Digital Therapeutics-Based Cardio-Oncology Rehabilitation for Lung Cancer Survivors: Randomized Controlled Trial. PMID 39999435 · JMIR Mhealth Uhealth · 2025-Feb-25 The study is a randomized controlled trial in human lung cancer survivors, but it evaluates a non-drug digital therapeutics-based telerehabilitation intervention and its primary endpoints are cardiopulmonary fitness (e.g., VO2 peak) and quality of life, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the drug intervention or time-to-event endpoint criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Assessing the uptake of the core outcome set in randomized controlled trials for coronary artery disease: a trial registry analysis. PMID 39994760 · Trials · 2025-Feb-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer. PMID 39879779 · Eur J Cancer · 2025-Feb-25 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Nivolumab and hypofractionated radiotherapy in patients with advanced melanoma: A phase 2 trial. PMID 39864364 · Eur J Cancer · 2025-Feb-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial. PMID 39864363 · Eur J Cancer · 2025-Feb-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial. PMID 39846936 · J Am Coll Cardiol · 2025-Feb-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials. PMID 39826197 · Eur J Cancer · 2025-Feb-25 The record is a pooled analysis across age subgroups from three randomized trials, not the primary result report of a single Phase III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial. PMID 39798264 · Eur J Cancer · 2025-Feb-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial. PMID 39671272 · JAMA · 2025-Feb-25 The study is a randomized, double-blind, Phase III oncology trial with a drug intervention (camrelizumab). However, its primary endpoint is pathological complete response (pCR), which is a binary endpoint, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) that would be analyzed with Kaplan-Meier methods or report a hazard ratio. The deterministic review correctly identified this as 'no_time_to_event_signal'. Therefore, it does not meet the requirement for a time-to-event primary or key secondary endpoint. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia. PMID 39626287 · Blood Adv · 2025-Feb-25 The study is an oncology randomized Phase 3 trial with drug intervention and original results, but the reported analysis is an ad hoc investigation of peripheral neuropathy symptom resolution and quality of life. It does not report a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or associated Kaplan-Meier/HR statistics. Therefore, it is ineligible for the KM digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM. PMID 39602342 · Blood Adv · 2025-Feb-25 The record describes a prespecified analysis from a randomized, phase-3 trial (FORUM) evaluating drug-containing conditioning regimens for allo-HSCT in pediatric ALL. It reports primary time-to-event efficacy endpoints (OS, EFS) and is an original result publication. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 1 Figure · 6 Panel · risk visible |
| Tenecteplase versus alteplase for acute ischaemic stroke in the elderly patients: a post hoc analysis of the TRACE-2 trial. PMID 38858097 · Stroke Vasc Neurol · 2025-Feb-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma. PMID 39994363 · Sci Rep · 2025-Feb-24 The record describes a Phase II/III randomized trial (implied by the definitive comparison and primary efficacy reporting in a completed study, despite not explicitly stating the phase in the abstract) comparing two drug-containing regimens for multiple myeloma, with PFS and OS as primary endpoints. All eligibility criteria are met. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 1 Figure · 2 Panel · risk not_visible |
| Plain versus drug balloon and stenting in severe ischaemia of the leg (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial. PMID 39993822 · BMJ · 2025-Feb-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial. PMID 39523543 · Clin Infect Dis · 2025-Feb-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of adaptive variable-resistance training on chemotherapy-induced sarcopenia, fatigue, and functional restriction in pediatric survivors of acute lymphoblastic leukemia: a prospective randomized controlled trial. PMID 39985582 · Support Care Cancer · 2025-Feb-22 This is a randomized controlled trial of a non-drug intervention (exercise) in pediatric ALL survivors. While it involves patients with a human malignant neoplasm and is a prospective randomized trial, it does not meet the core eligibility criteria: 1) It is not a Phase III/IIIb or Phase II/III trial (no phase specified in metadata, likely an early-phase or single-center trial), and 2) The primary efficacy endpoints are not time-to-event (e.g., OS, PFS) but are functional, morphological, and patient-reported outcomes measured at baseline and post-intervention. The drug intervention criterion is met only peripherally as patients are 'cancer survivors' who have completed chemotherapy, but the trial itself tests an exercise intervention, not a drug therapy. Therefore, it is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. PMID 39919773 · Lancet · 2025-Feb-22 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Efficacy and Safety of Pelubiprofen in the Treatment of Acute Upper Respiratory Tract Infection: A Multicenter, Randomized, Double-Blind, Non-Inferiority Phase III Clinical Trial Compared to Loxoprofen. PMID 40094866 · J Clin Med · 2025-Feb-21 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study. PMID 39993074 · Medicine (Baltimore) · 2025-Feb-21 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Intermittent screening using ultra-sensitive malaria rapid diagnostic test and treatment with pyronaridine-artesunate compared to standard preventive treatment with sulfadoxine-pyrimethamine for malaria prevention in pregnant women in Kinshasa, DRC. PMID 39985024 · Malar J · 2025-Feb-21 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Single- versus multi-fraction spine stereotactic radiosurgery (ALL-STAR) for patients with spinal metastases: a randomized phase III trial protocol. PMID 39984889 · BMC Cancer · 2025-Feb-21 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Examining the Implementation of the Italian Version of the Teen Online Problem-Solving Program Coupled With Remote Psychological Support: Protocol for a Randomized Controlled Trial. PMID 39984161 · JMIR Res Protoc · 2025-Feb-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Lepalvir: Biomaterial efficacy and safety for patients with acute ischemic stroke. PMID 39925427 · iScience · 2025-Feb-21 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Candidate Ac3-S-LPS Vaccine Against S. flexneri 1b, 2a, 3a, 6, and Y Activates Long-Lived Systemic and Mucosal Immune Responses in Healthy Volunteers: Results of an Open-Label, Randomized Phase 2 Clinical Trial. PMID 40266069 · Vaccines (Basel) · 2025-Feb-20 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The ATLAS/NOA-29 study protocol: a phase III randomized controlled trial of anterior temporal lobectomy versus gross-total resection in newly-diagnosed temporal lobe glioblastoma. PMID 39979825 · BMC Cancer · 2025-Feb-20 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effects of transcutaneous auricular vagus nerve stimulation on postoperative delirium in older patients with hip fracture: protocol for a randomised controlled trial. PMID 39979049 · BMJ Open · 2025-Feb-20 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. PMID 39976417 · N Engl J Med · 2025-Feb-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Telpegfilgrastim for chemotherapy-induced neutropenia in breast cancer: A multicenter, randomized, phase 3 study. PMID 39820410 · Chin Med J (Engl) · 2025-Feb-20 Metadata (title) explicitly indicates a randomized phase 3 trial with a drug intervention for an oncology population. However, the primary endpoint is not specified as a time-to-event efficacy endpoint (e.g., OS, PFS); it appears to focus on neutropenia (a supportive care/safety outcome). The abstract is unavailable, preventing confirmation of a key efficacy endpoint, time-to-event analysis, or original result status. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH. PMID 39700502 · Blood · 2025-Feb-20 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years. PMID 39671537 · J Clin Oncol · 2025-Feb-20 命中用户提供的消化道肿瘤阳性参考集。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblepositive_reference | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial. PMID 39556780 · J Clin Oncol · 2025-Feb-20 The record describes a randomized trial with a drug intervention and OS as the primary time-to-event endpoint. However, the provided metadata (publication types, mesh, abstract) does not explicitly confirm the trial phase as Phase III/IIIb or Phase II/III, which is required for eligibility. The deterministic review flagged 'phase3_evidence_unclear'. Without explicit phase information, a definitive eligibility determination cannot be made. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. PMID 39453837 · N Engl J Med · 2025-Feb-20 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. PMID 39441941 · Blood · 2025-Feb-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Time to return of bowel function following perioperative probiotics in colorectal cancer surgery (PICCS-1): study protocol for a randomized controlled trial. PMID 39972354 · Trials · 2025-Feb-19 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Targeting autophagy in platinum-sensitive relapsed ovarian cancer: randomized phase II trial of hydroxychloroquine with chemotherapy with biomarker correlation. PMID 39969689 · Discov Oncol · 2025-Feb-19 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| 6-mm vs 10-mm diameter fully covered self-expandable metal stents in patients with unresectable malignant distal bile duct stricture (COSMIC UNISON): study protocol for a multicenter, randomized controlled trial. PMID 39966935 · Trials · 2025-Feb-18 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Evaluating a digital prehabilitation tool in patients with colorectal surgery: protocol for a multisite randomised controlled trial. PMID 39965940 · BMJ Open · 2025-Feb-18 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial. PMID 39889711 · Cell Rep Med · 2025-Feb-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis. PMID 39657020 · Br J Dermatol · 2025-Feb-18 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From Two Randomized, Double-Blind, Placebo-Controlled, Phase III Studies. PMID 39475143 · Aesthet Surg J · 2025-Feb-18 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Longitudinal validity of the Hyperhidrosis Quality of Life Index (HidroQoL©) in a phase IIIb clinical trial population with hyperhidrosis: responsiveness and meaningful change. PMID 39467334 · Br J Dermatol · 2025-Feb-18 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial. PMID 39437312 · Br J Dermatol · 2025-Feb-18 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of a Targeted Concurrent Training Program on the Exercise Adherence in Female Breast Cancer Survivors: A Randomized Controlled Trial. PMID 39997304 · Healthcare (Basel) · 2025-Feb-17 The record describes a randomized controlled trial in breast cancer survivors, but the intervention is a physical activity program (non-drug). There is no drug-containing intervention. The primary outcome is physical activity time/intensity, not a time-to-event efficacy endpoint (e.g., OS, PFS). There is no evidence of Phase III or definitive trial design. Therefore, it does not meet the core eligibility criteria for a drug-containing oncology trial with a time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative analysis of intestinal tumor segmentation in PET CT scans using organ based and whole body deep learning. PMID 39962481 · BMC Med Imaging · 2025-Feb-17 The record is an original comparative study from a phase III randomized trial (NCT01287741) in oncology (lymphoma). However, it is not eligible because (1) it does not involve a drug intervention—it compares deep learning image segmentation methods—and (2) it does not report a time-to-event efficacy endpoint (e.g., OS, PFS). The primary outcomes are segmentation performance metrics (Dice score, precision, recall, F1-score). |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Randomized controlled trial on the efficacy of topical urea-based cream in preventing capecitabine-associated hand-foot syndrome. PMID 39962445 · BMC Cancer · 2025-Feb-17 The study is a randomized, Phase II/III trial in oncology with a drug intervention, but it evaluates the prevention of a treatment-related adverse event (hand-foot syndrome) as its primary efficacy endpoint. It does not report a time-to-event efficacy endpoint such as overall survival, progression-free survival, or disease-free survival with Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the key inclusion criterion for a Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A patient-reported outcome measure comprising the stool frequency and abdominal pain items from the Crohn's Disease Activity Index: psychometric evaluation in adults with Crohn's disease. PMID 39962027 · J Patient Rep Outcomes · 2025-Feb-17 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The LYMPH trial: comparing microsurgical with conservative treatment for chronic breast cancer-associated lymphoedema - study protocol of a pragmatic randomised international multicentre superiority trial. PMID 39961719 · BMJ Open · 2025-Feb-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |